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Introduction
Radiation therapy is entering into a new era, in which
radiation and molecular biology are the objects of incre-
asing interest, and they are quickly coming into the use for
clinical practice. Recent advances in computer-controlled
treatment machines have allowed the 3D-conformal opti-
mization techniques (3D-CRT) to become as important as
new biological tools for the improvement of therapeutic
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A 3D – conformal optimization techniques (3D-CRT) became an important tool for the improvement of therapeutic gain. In-
tensity-Modulated Radiation Therapy (IMRT) is one step further and it offers intriguing challenge to conformal spatial distri-
bution of the prescribed dose to the tumour target and to spare critical normal tissues. Six different prospective treatment plans
for locally advanced lung cancer were used to analyse advantages and limitations for the IMRT. The respective DVHs are con-
verted into Biologically Normalized DVHs (BNDVH) and limitations of large and small penalty factors are discussed.
BNDVHs shows substantial differences in the distribution of “biological” doses as compared with physical DVHs. Even a small
geographical miss due to set-up error has significant impact on the predicted uncomplicated TCP.
The results of radiobiological simulations suggest that IMRT may increase the steepness of TCP leading to higher therapeu-
tic benefit. Furthermore, altered hyperfractionated irradiation allows to increase “biological” dose within the target without in-
crease the risk of late complications. Because of the potential risk of geographical miss in IMRT, physical DVHs should be co-
nverted into BNDVHs and more than one biological penalty factor should be considered, especially in the case of large volu-
mes of critical organs.
Fizyczne i radiobiologiczne podstawy korzyÊci i ograniczeƒ
w radioterapii z modulacjà intensywnoÊci dawki (IMRT)
Techniki trójwymiarowego planowania radioterapii dostosowawczej (3D – CRT) stworzy∏y mo˝liwoÊci zwi´kszenia biologicz-
nego zysku terapeutycznego. Radioterapia z modulacjà intensywnoÊci dawki (IMRT) jest kolejnym krokiem post´pu w radio-
terapii i oferuje mo˝liwoÊç dostosowania zaplanowanej dawki promieniowania do obszaru guza nowotworowego, z jednocza-
sowà ochronà zdrowych tkanek. Analizie poddano 6 ró˝nych planów leczenia promieniami chorych na miejscowo zaawan-
sowanego raka p∏uca i oceniano korzyÊci oraz ograniczenia wynikajàce z zastosowania IMRT. Fizyczne histogramy
Dawki-Obj´toÊci (DOH) przeliczono na Biologicznie Znormalizowane DOH (BZDOH) i oceniono wp∏yw ma∏ych i du˝ych
czynników ograniczajàcych dla tkanek zdrowych. Stwierdzono wyraêne ró˝nice w rozk∏adzie dawek biologicznych w BZDOH
w porównaniu do „fizycznych” DOH. Nawet niewielki „b∏àd geograficzny”, wynikajàcy z niedostatecznej precyzji w pozycji
i unieruchomieniu chorego, ma znamienny wp∏yw na przewidywanà szans´ miejscowego wyleczenia (TCP), bez powik∏aƒ po-
promiennych.
Wyniki symulacji radiobiologicznej wskazujà, ˝e IMRT mo˝e wp∏ynàç na zwi´kszenie kàta nachylenia krzywej TCP i w ten spo-
sób zwi´kszyç zysk terapeutyczny. Ponadto, zmienny sposób hiperfrakcjonowanego napromieniania umo˝liwia zwi´kszenie
„dawki biologicznej” w obszarze guza, bez wzrostu ryzyka póênych powik∏aƒ. IMRT wià˝e si´ z ryzykiem „b∏´du geograficzne-
go”, dlatego fizyczne DOH powinny byç uzupe∏nione o BZDOH i w przypadku du˝ej obj´toÊci narzàdu krytycznego nale˝y
uwzgl´dniç wi´cej ni˝ jeden czynnik ograniczony.
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gain. Intensity-Modulated Radiation Therapy (IMRT) is
one step further in computer-aided optimization. In this
approach intensity distributions within each of a set of
beams are determined by the mathematical inversion of
a desired dose distribution. The IMRT offers intriguing
challenge to conformal spatial distribution of the prescri-
bed dose to the tumour target and to spare critical normal
tissues.
However, even with IMRT, it is impossible to achie-
ve the ideal dose distribution, that is, 100% dose in the tu-
mour and 0% in the surrounding critical tissues. The
IMRT planning can be considered optimal if it leads to
a dose distribution that is as close to the desired dose di-
stribution as physically possible. One important concern is
that the objectives of optimization are only surrogates of
the desired clinical outcome, and physical optimum does
not necessarily mean radiobiological optimum. Thus, it se-
ems important to consider both physical and radiobiologi-
cal criteria in the IMRT treatment planning to achieve
physically and biologically optimal beam profiles which
may results in complication – free tumour control [1, 2, 3].
Among many tumour sites and stages, non-small cell
lung cancer patients (NSCLC) with locally advanced and
unresectable tumour mass are likely to be important can-
didates to the IMRT. About 30-40 % of patients with
NSCLC have no metastases, but locally advanced tumour
at the time of diagnosis, and they are potentially curable
by radiotherapy combined or not with chemotherapy.
However the results of conventional treatment with 60-65
Gy are generally poor mainly due to the frequent inabili-
ty of local tumour eradication which likely leads to the la-
ter development of distant metastases. The 3D-CRT or
IMRT offer the potential to escalate the dose to the target
with concomitant relative sparing of normal tissues
The present paper analyzes biological and physical
aspects of the IMRT planning compared with 3-D confor-
mal and conventional techniques using different fractiona-
tion schemes.
Methods and materials
The IMRT technique using the Helios programme has been
used for the last 7 months at the Centre of Oncology in Gliwice.
To search for optimal physical and biological dose delivery, six
categories of data were included in the analysis.
Tr e a t m e n t  t e c h n i q u e s
Six different prospective treatment plans are used: (1) IMRT
as a sole treatment; (2) IMRT with simulation of a small (1-2
mm) geographical miss of tumour mass reflecting set-up error;
(3) IMRT as a boost of 20 Gy to 3D-CRT of 50 Gy; (4) 3D-
-CRT with MLC; (5) conventional stationary 50 Gy + 3D-CRT
boost of 20 Gy, and (6) conventional AP-PA two fields stationa-
ry technique. For all six examples dose fractionation of 70 Gy in
35 fractions in 49 days was assumed as physical standard.
DVH and BNDVH
Six physical dose-volume histograms (DVH) were used to find
the optimal solution. The merit of IMRT is seen in its ability to
reduce dose to the most radiosensitive structures and to deliver
it homogeneously into the target (tumour) which needs a high
dose to be controlled. The strategy should be therefore to find
the best plan within physical limits. Before doing this, one has to
define clinically meaningfull objectives and constraints. At first
glance it may look simple, but it is, in fact, one of the most criti-
cal and important elements of the radiotherapy planning. The
optimization objectives and constraints proposed and imple-
mented up to now can be classified into physical and radiobiolo-
gical criteria. Combination of both types have to be considered.
Physical criteria mean the criteria that can be expressed in
terms of well-defined and measurable physical quantities, such as
dose and volume.
Based on Bartfeld [4] suggestions, a simple constraint as
the limitation of maximal dose in critical organ to the accepted
tolerance level is usually used. Since lungs are critical normal
structures with a large volume effect the use of a strict constra-
int is sometimes too restrictive to be fulfilled especially when the
critical organ is in the immediate neighbourhood of the target
volume or surrounding it. Therefore, the constraint is often rela-
xed by introducing a weighting factor, called as a penalty fac-
tors. A small penalty factor allows for some overdose beyond the
limit as its consequence is only a relative mild reaction. For lung
no more than 30 Gy to 10% of the whole organ was assumed.
A large penalty factor however would not allow any overdose
because it may lead to complications which have to be prevented
by all means: thus it was assumed that 33% of lung volume sho-
uld not receive more than 15 Gy. In contrast the large penalty fac-
tor for spinal cord is very restrictive and defines 0% of volume
for dose higher than 45 Gy. Penalty factors are visualized as
a barrier with a corner at the point (DmaxVmax) in the DVHs, and
can be defined as proportional to the square of the excess dose
beyond the tolerance.
To assess radiobiological criteria, according to Niemierko
[5, 6], DVHs are converted into Biologically Normalized histo-
grams (BNDVH) using the of modified linear-quadratic formu-
la to normalize dose fractionation to that if given in 2 Gy frac-
tions:
NTD2.0 = TDi (α/β+ di) / (α/β+ 2.0)
where NTD is normalized equivalent dose, TDi is physical total
dose given in fractions of di. α/β ratios of 15.0 Gy for tumour, 3.0
Gy for lung and 2.0 Gy for spinal cord have been used. The
BNDVH curves for tumour and critical organs were recalculated
for change in dose per fraction from 2.0 Gy to 1.5 Gy and 1.2 Gy
and for hyperfractionated escalated schedule to increase local tu-
mour control probability (TCP). Correction for change in overall
treatment time is not accounted for the analysis.
T C P  a n d  d o s e  f r a c t i o n a t i o n  o p t i m i z a t i o n
For beneficial outcome with complete and long term tumour
control, no tumour clonogens must survive. Thus, the relation-
ship between tumour cure probability (TCP) and dose is de-
scribed by a sigmoid curve. According Poisson statistics TCP
correlates with the average number of surviving clonogenes per
tumour by the following formula [4, 5]:
TCP = e-x
Because the x is the product of surviving fraction (SF) and
initial cell number (M), (x = SF x M), and SF is a function of to-
tal dose and effDo (effDo is the average fractionated dose necessa-
ry to reduce survival to 0.37 (e-1), – SF = e -TD/effDo, therefore the
increase of TD by three effDo is sufficient to increase the TCP
from 10% to 90%.
This simple relationship implies that any increase in the
TCP (i.e. from TCPi to TCPz) would need n x effDo increase in
total dose, where n = Ln (Ln TCPi/Ln TCPz). Thus any change
in TDi ((D) would produce change in TCPi into TCPz by
Ln TCPz = Ln TCPi / e – (∆D/effDo)
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For the present calculation an effDo of 5 Gy was used as sugge-
sted by Howard Thames.
The same method can be used to search the impact of he-
terogeneity in dose distribution on change in Normal Tissue
Complication Risk (NTCR). The way how to incorporate this
concept into BNDVHs is described by Brahme in details else-
where [3].
Using Choi data sets [7] for local control for lung cancer
and data sets of Rubin et al. [8], Keane [9] Philips and Margo-
lis [10] for late severe complication of in the lung and spinal
cord the respective dose response curves were estimated. From
the analyzed BNDVHs total doses for various fractionation
scheme are subtracted to estimate changes in the TCP and
NTCR depending on the BNDVH dose distribution and fractio-
nation.
R a d i a t i o n  T h e r a p y  O p e r a t i o n  C h a r a c t e r i s t i c
( RT O C )
To analyze advantages and traps of the IMRT related to various
techniques and the risk of geographical miss due to set-up error
it is important to estimate the probability of uncomplicated tu-
mour control, that is therapeutic gain. The space in which opera-
tional decisions are made is represented by so called RTOC
space – “two times two squares” restricted by dose-related con-
tinuum of the TCP and of the NTCR (Pi). This concept was
proposed for radiotherapy in 1985 by Andrews [11] and used by
Agren et al. [1] to optimize radiation treatment for head and
neck tumours.
Diagonal lines (solid) in Fig. 8A called iso-utility or iso-be-
nefit curves conform with the equation:
TCP x (1 – Pi) = k
which means the probability of benefit times the probabili-
ty of no complication (that is,1 – Pi) is a constant value “k”.
From this, for a given “k” value, as the TCP increases the proba-
bility of no complication decreases. In clinical situation there
are many pairs of TCP and Pi but there is the only one pair that
is optimum for a given therapeutic situation (the highest TCP
and the lowest Pi).
The RTOC space is splited by iso-benefit curves and each
one curve corresponds to a specific “k” value. Using clinical da-
ta (pairs or TCP and Pi) for a given fractionation schedule or tre-
atment technique probabilities of both benefit and complica-
tion are monotonic increasing with dose and presented as an
asceding curve bending upward and outward to the right. At
some point this curve becomes the tangent to the highest attaina-
ble iso-benefit curve which provides the highest “k” value for the
optimal treatment conditions. This sort of analysis seems extre-
mely important when the IMRT advantages are weighted against
physical and biological traps.
Results and discussion
Figures 1, 2 and 3 show examples of physical dose distri-
bution for option (1), (2), (3). Table I includes physical do-
ses within the target and critical organs. At first glance, it
may look there is no significant difference in dose delive-
red to the target when conventional, conformal or IMRT
technique are used. However there is substantial sparing
effect of critical organs in favour of the IMRT, but at this
level it is difficult to decide which option is objectively
optimal.
The next step is the analysis of DVHs. Three DHVs
for the respective treatment techniques have been chosen
for the presentations and converted into BNDVHs, i.e.
for the IMRT alone, IMRT as 20 Gy boost to conformal
(MLC) technique and IMRT with set-up error (geogra-
phical miss). The IMRT alone (Fig. 4) dose distribution in
critical organs do not exceed penalty limitations (Tab. II)
and shows optimal solution for both the target and the cri-
tical organs. IMRT as a boost (Fig. 6) could be considered
as feasible one, however 26% of lung volume receiving
the dose above the threshold level makes this option
unacceptable. In contrast, BNDVH for IMRT with set-up
error (Fig. 5) shows dose distribution in lung below large
penalty barrier but for spinal cord even 1% above penal-
ty barrier can not be accepted.
For the target, it looks much worse because 40% of
tumour volume would receive the dose lower than Dmod
(Tab. II). Figure 6 shows that for the IMRT given as a bo-
ost, doses higher than 70 Gy cover more than 90% of
target volume compared to 70% of target volume in the
case of IMRT alone.
Since, as yet, there is limited experience as to what is
achievable with intensity modulated beams, even small
target underdosage may produce radiobiological “double-
Tab I. Physical dose in the target and critical organs depending on the technique of radiation treatment of the lung cancer
Target Lung Spinal cord
Technique VOL. Dmod. Dmin. Vol. Dmax. Vol. Dmin.
(cm3) (Gy) (Gy) (cm3) (Gy) (cm3) (Gy)
(1) IMRT 120 70.7 ± 4.3 53.1 3350 55.2 ± 14.1 56.9 34.1 ± 14.8
(2) IMRT (mov.) 118 70.3 ± 5.4 43.6 3400 63.4 ± 14.3 ” 33.6 ± 15.0
(3) (AP – PA) + IMRT (boost) 119 72.0 ± 4.2 63.7 3600 65.2 ± 10.2 ” 58.7 ± 9.5
(R) 76.6 ± 12.6
(4) CONFORMAL (MLC) 119 70.0 ± 7.3 37.3 3651 59.5 ± 7.3 ” 25.7 ± 11.3
(R) 71.3 ± 20.2
(5) (AP – PA) + CONFORMAL (MLC) 120 70.7 ± 5.3 33.8 3220 65.2 ± 11.6 ” 28.3 ± 16.3
(R) 72.4 ± 26.7
(6) CONVENTIONAL (AP – PA) 120 74.5 ± 2.4 57.3 3137 73.7 ± 17.5 ” 72.4 ± 46.1
(R) 77.5 ± 43.9
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-trouble” that is not clinically acceptable. Therefore, the
optimum dose distribution for IMRT defined by so called
“closeness” should be considered in the sense that it will
lead to a dose distribution which is as close to the desired
distribution as physically and radiobiologically possible.
A physical DVH might be considered as optimum where-
Fig. 2. Dose distribution for lung cancer using IMRT with geographical miss within the target volume
Fig 1. Dose distribution for lung cancer using IMRT-alone
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as radiobiologically it is not necessarily true and the rever-
se may also happen when the dose distribution within
critical organs exceeds the prescribed limit whereas the
normalized DVH (BNDVH) satisfies the prescribed con-
straints (Fig. 4-6, dashed lines).
For the present examples the main goal was to deli-
ver 70 Gy in 35 fractions to the planning target volume
(PTV) while keeping the dose of 46 Gy to spinal cord
and of no more than 30 Gy to more than 10% of the lung
volume. Generally the critical organs are assigned a prio-
rity relative to the target volume. Besides penalty limits
the scheme of dose fractionation plays also an important
role. Because late responding normal tissues are signifi-
cantly more sensitive to change in dose per fraction, any
decrease in fraction size below 2 Gy may have important
impact on dose distribution curves within these tissues.
For IMRT alone (Fig. 4) and IMRT with set-up error
(Fig. 5), for dose per fraction smaller than 2 Gy the
BNDVH curves for spinal cord and lung (dashed lines)
are shifted to the left, below penalty limits. It has to be po-
inted out that this effect is only due to the change in dose
fractionation but not the results of changes in the number,
Tab. II. Physical (TD) and biologically iso-effective (NTD) dose distribution in tumour and critical organ volumes depending of
radiotherapy techniques (* Normalized Total Dose given in 1.2 Gy fractions, iso-effective to 70 Gy)
Tumour Lung Spinal cord
Technique TDphys. NTD ISO-NTD1.5(1.2)* TD NTD1.5(1.2)* TD NTD1.5(1.2) *
for d=1.5Gy for 70 Gy
(α/β= 15 Gy) (α/β= 3.0 Gy) (α/β= 2.0 Gy)
< 70 Gy > 30 Gy > 46 Gy
(1) IMRT 30% ⇒ 45% 11% 17% 8% 2% 0%
(2) IMRT (mov.) 40% ⇒ 65% 17% 18% 0% 1% 0%
(3) (AP – PA) MLC + IMRT (boost) 7.5%* ⇒ 75% 0.5%* (R) 27% (R) 26%*! 45% 25% (0%*)
(4) CONFORMAL (MLC) 80% ⇒ 95% 60%! 3% 2% 0% 0%
(5) (AP – PA) + CONFORMAL (MLC) 50% ⇒ 85% 20% 11% 10% 0% 0%
(6) CONVENTIONAL (AP – PA) 3% ⇒ 20% 0%! 8% 7% 52%! 48%*!
% VOLUME
Fig. 3. Dose distribution for lung cancer using IMRT for 20 Gy boost
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angle and weight of the beams. In contrast, the IMRT
boost option (Fig. 6) shows that although the NTCR for
spinal cord may drop down to less than 1% by decreasing
the fraction size from 2.0 Gy to 1.2 Gy, the modified frac-
tionation does not change the already high NTCR for ri-
ght lung (large penalty limit) which is even around 90%
for about 15% of lung volume. It makes the IMRT-boost
option unacceptable. For the next two options (4) and
(5) the NTCR for spinal cord has been maintained at
0% level independent of dose fractionation (Tab. II). The
conventional option (6) is totally unacceptable.
For anatomic structures such as lung where the volu-
me effect is large and the tolerance in relatively low, the
IMRT tries to balance the desire to reduce the dose out-
side the target volume against the desire to maintain uni-
form dose in the target volume, resulting in inhomogene-
ous dose distribution, even at the cost of allowing a small
amount of lung volume to receive higher dose. Howe-
ver, the reduction of the dose around the target periphe-
ry may result in an inhomogeneous dose pattern in the
target. It might be serious biological trap (double-trouble)
if only the purely physical dose-based objectives are con-
sidered. Therefore, optimization of the dose intensity di-
stribution may fail to yield better results unless such bio-
logical indices as the TCP, TCR and volume effect are
accounted for. Table II illustrates a substantial TCP decre-
ase reflecting the dose gradient within the target volu-
me. The physical “cold spots” in the target enlarge by
15-20% when the effect of dose fractionation is taken in-
to account, and for the IMRT-boost option by even
67.5%. It will result in dramatic decrease of the TCP.
One has to bear in mind that a standard 70 Gy in 2 Gy
fractions is not biologically the same as 70 Gy in 1.5 Gy or
1.2 Gy fractions. Furthermore, a dose gradient within the
target reflects indirectly a gradient in fraction size if the
number of fractions is constant. Thus, the target dose cu-
rves are shifted to the left in BNDVHs (Fig. 4-6) and the
target volume outside of the desired dose constraint enlar-
ges.
Despite the rearrangement of the angles and we-
ights of the beam improvement of dose distribution can
be achieved by changing dose fractionation. It seems the
decrease of fraction size and the use of twice-a-day frac-
tionation (b.i.d.) could be a useful method to reduce hete-
rogeneity of dose distribution in the target volume (cold
spots), and consequently to increase the TCP. Using smal-
ler doses per fraction it is important to correct total dose
as biologically equivalent to the designed dose (iso-
-NTD1.5 eq. 70 Gy in Fig. 4-6). It shifts the respective
target-dose to higher doses, and results in a pronounced
increase of the target volume uniformly covered by the
designated dose (i.e. from 70% to 89% for the IMRT-
Fig. 4. Biologically Normalized BNDVH for lung cancer
(IMRT-alone).
Solid lines represent tumour and lung, dotted line is for spinal cord – all
represent 2.0 Gy conventional fractionation. Dashed lines (shifted to
the left) illustrate respective biologically equivalent doses if given in 1.5
Gy fractions. Dashed lines for tumour (shifted to the right) represent
hyperfractionation b.i.d. given in 1.5 Gy fractions (NTD1.5 eq, 70 Gy).
Fig. 5. Biologically Normalized BNDVH for lung cancer (IMRT with
geographical miss within the target). Legend as in Fig. 4.
Fig. 6. Biologically Normalized BNDVH for lung cancer (IMRT for 20
Gy boost). Legend as in Fig. 4.
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-alone option – Tab. II). Moreover, the use of smaller
doses per fraction (i.e. hyperfractionation) is in favour
of late responding normal tissue because tolerance dose
for small and large lung volume increases by 11%, i.e.
from 30 Gy to 33.3 Gy and from 15 Gy to 16.6 Gy re-
spectively, and from 46 Gy to 52.5 Gy for spinal cord, re-
sulting in displacement of the respective penalty limits
to higher doses on the BNDVHs. It suggests that changes
in dose fractionation might be advantageous for both
TCP and NTCR and be useful for comparing rival plans
and for optimization, because for the IMRT it may decre-
ase the dose to the target volume in order to ensure a low
enough dose to the lung and to the spinal cord.
Geometric  uncertainty set-up error,  volume
effect
In 1978, Hendrickson [12] considered the precision of
radiation delivery system and specified the four P's of
human error: precision of daily dose delivery, prescription
of tumour dose, physical dosimetry, and planning of an in-
dividual's treatment. All criteria for the GTV, CTV, PTV
and Organ at Risk margins, set-up error, patient move-
ments and managing geometric uncertainties in the IMRT
are presented in details by Jaffray et al. [13] and Ekberg et
al. [14], and it is not the aim of this paper to discuss these
problems. It becomes clear that biological optimization of
the IMRT needs to take into account all uncertainties
concerning target volume, critical organ, safely margins in
relation to the anatomical structures. Any geometric (do-
simetric also) error leads to geographical miss which must
be considered as the major trap for the IMRT planning.
Missing the a tumour mass by even 1-2 mm is detrimental
for treatment outcome and maybe the cause of dramatic
decrease in the TCP, independently on how sophisticated
the used technique of irradiation.
Using PVI and dosimetry in vivo we have found that
the set-up error standard deviation is on average 2.49
mm ±1.23 mm in all directions for 15% of irradiated pa-
tients, and the dosimetric error of ±6% for 11% of pa-
tients. Although all these errors have been corrected it im-
plies that the QA procedures as it is proposed by Bartfeld
[4] and Ekberg et al. [14] must be fulfilled in all steps of
inverse planning to avoid the risk of getting trapped in lo-
cal minima within the target volume.
The effect of geographical miss is simulated on Figu-
re 2 and Figure 5. Although dose distributions in spinal
cord and lung are acceptable, a substantial dose gradient
below the desired dose for more than 40% of the target
volume makes this option not feasible.
The volume-effect is an important constraint for the
IMRT technique. This objective can be specified only in
terms of the desired dose or dose ranges in the critical or-
gan, and it becomes crucial for large volumes, such as
lung. Incorporating volume effects in a limited manner by
dividing normal tissue into multiple regions will not solve
the general problem since there is an infinitive number
combinations of dose and volume that lead to the same
clinical end-point [2, 6]. This is better to incorporate volu-
me-effect in a form consistent with the way critical or-
gan responds to radiation, namely in the form of NTCRs.
To compute the NTCR one can employ a version of
Lyman's model [15], in which volume effect can be expres-
sed in the form of a power law, that is:
TD5/50 (Vi) = TD5/50 (1) / Vi n
where TD5/50 is the tolerance dose for 5% or 50% NTCR
for a uniformly irradiated organ and TD5/50 (Vi) is the re-
spective tolerance dose when only a fraction Vi of the
whole volume is irradiated. The parameter “n” reflects
the magnitude of the volume effect. For small organs,
such as the spinal cord or the rectum, “n” is small. For
large volume such as the lung, “n” is large. Mohan et al.
[2] estimated an “n” value of 0.12 for the rectum, 0.87 for
the lung and 0.05 for the spinal cord. It shows that for
spinal cord volume-effect is of less importance, and it
does not matter whether short or long sections of the
spinal cord are involved, the TD does not change a lot,
whereas for the lung volume-effect it plays a major role.
For the present analysis a simple way of volume-effect es-
timation has been used. According to Rubin et al. [8]
large penalty limit of 15 Gy for more than 66% of the
lung volume and a large penalty a factor of 30 Gy for
more than 10% volume have been chosen. According to
Lyman's equation the latter one could even be larger,
up to 42.4 Gy or up to 47 Gy for 1.5 Gy dose per frac-
tion*).
Therefore, considering penalty limits for the lung
the BNDVHs (Tab. II) all technique options are accepta-
ble except the IMRT-boost option [3]. This option was
used as an example to illustrate that BNDVH for two
lungs should be considered separately because biologi-
cal dose distribution for one lung could be within the li-
mits whereas it does not in the second one (Fig. 6). Fur-
thermore, it seems practically useful to incorporate to
the BNDVH two penalty limits, for small and medium
volume if a total volume of the critical organ is large.
L o w  d o s e  t r a p
There is radiobiological evidence that within the region of
very small doses per fraction (below 1.0 Gy) the L-Q mo-
del may underestimate iso-effectiveness of small doses
because the initial small part of cell survival curve is pro-
*) assuming that 33% of the lung volume can receive TD5 = 15 Gy
thus 10% of the volume will receive:
V corr = Vxn / Vi n
= 0.10 0.87 / 0.33 0.87
= 7.413 / 2.62
= 2.82
Thus TD5(10% V) = TD5(33% V) x 2.82
= 42.4 Gy
If 1.5 Gy fractions will be used instead of 2.0 Gy, the TD 5(10%) can
even increase to
TD5(10%)1.5 Gy = 42.4 Gy (α/β+ 2.0) / (α/β+ 1.5)
= 42.2 x 1.11
= 47 Gy
assuming that α/β ratio = 3 Gy
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bably very steep and much steeper than that for the range
of higher doses. Thus 20 Gy in 35-40 fractions could be as
risky as 70-80 Gy in the same number of fractions. Becau-
se the IMRT offers a high and rapid gradient of dose wi-
thin the irradiated volume, peripheral regions close the
skin surface could be at a similar risk of late normal tissue
effects as the part of critical organs receiving high dose gi-
ven in 2 Gy fractions. This suggestion comes from experi-
mental studies as yet, and it is not documented in the cli-
nic. However, this problem should not be ignored.
RT O C  o p t i m i z a t i o n
Based on the results of step-analyses which have been
performed till now, optimization of dose distribution and
dose fractionation seems to purely arbitrary and subjecti-
ve. The RTOC model is the objective way to estimate the
optimal therapeutic dose level and its distribution produ-
cing the highest TCP and the lowest NTCR possible [1,
11]. For the present study the RTOC is used as an exam-
ple to demonstrate the way in which it can be incorpora-
ted into the IMRT planning, as its final step.
To estimate standard (conventional) dose response
curve for the tumour (TCP) and for the normal lung
(NTCR) clinical data concerning lung cancer control and
late fibrosis in the lung have been extracted from the lite-
rature [7, 8, 9, 10], and the respective dose-response cu-
rves are shown in Figure 7A. Dashed line shifted to the
left represents the NTCR for late lung fibrosis if large
volumes of critical organ are involved. It is much steeper
than the respective NTCR curve for small volumes of the
lung (solid line). The dotted line represents late complica-
tion-free tumour control probability (therapeutic gain)
it shows a very narrow “therapeutic window” suggesting
that using conventional stationary technique and dose
fractionation to the lung cancer patient one may not
expect significant improvement in the TCP without in-
crease in the risk of late complications.
The therapeutic advantage of the IMRT is clearly
illustrated in Figure 7B. The dose to the tumour is signi-
ficantly higher due to dose escalation and hyperfractiona-
tion and the respective TCP curve becomes steeper than
that for conventional stationary treatment (Figure 7B). At
the same time, the dose to the lung is reduced (dose gra-
dient in BNDVH and sparing effect of lower dose per
Fig. 7. Tumour Cure Probability (TCP) and late complications (LE) dose-response curve for lung: (a) conventional treatment planning and fractionation;
(b) IMRT with dose escalation of 70 Gy; curves (a) and (b) represent LR for treatment with 1.5 Gy and 1.2 Gy fractions respectively; (c) IMRT with the
decrease in effective TD by 5% due to geographical miss. In all figures dotted line represents late complication-free TCP which is considered as
a therapeutic gain.
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fraction) and the NTCR curves are shifted to the right in-
to the region of higher tolerance doses. As the result, the
“therapeutic window” is opened up substantially and the
peak of the bell-shaped curve (dotted lines in Fig. 7B)
for complication-free TCP increases from 55% to 73%
(Fig.7B-a), and even to 82% (Fig. 7B-b) if the dose per
fraction of 1.2 Gy is used (Tab. III). This significant incre-
ase of therapeutic gain can be achieved because physi-
cal optimization of the IMRT is strengthened by radiobio-
logical effect of escalated dose fractionation.
Figure 7C illustrates therapeutic trap as the effect of
geographical miss. It is not the aim of this paper to discuss
all situations and factors leading to such trap but even
5% decrease in the desired effective dose within a small
part of the tumour volume can neutralize the advantages
of IMRT by flattening the TCP curve, and the bell-shaped
curve automatically drops down to 53% (Tab. II).
Dose-response curves in Fig. 7 are the source of
TCP and NTCR paired values for continuously incre-
asing dose units. They have been used to construct the
RTOC curves in Figure 8 and to estimate iso-utility “k”
values for the analyzed IMRT options. This method offers
the objective choice of the optimal technique and dose
fractionation options. The “k” values established from
the RTOC curves (Tab. III) describe optimal therapeutic
gain (TG). The TG is the difference between TCP and
NTCR rates for given “k” values. The IMRT alone gives
20% increase in the TG (complication-free TCP) compa-
red with conventional stationary treatment. Further incre-
ase in the TG can be expected for the IMRT combined
with altered dose fractionation for which the highest “k”
value of 0.721 reflects 70% increase in the TG, and it is
optimal IMRT option.
Tab. III. Maximal iso-benefit “k” values taken from Figure 3
and the respective TCP  and LER (Late Effect Risk)
values corresponding with optimal fractionation schedules
Technique k- value TCP LER Fractionation *
Conventional 0.397 55% 25% 46 Gy/23fx./32 d.
IMRT 0.567 73% 22% 48 Gy/32 fx./16-21 d.
IMRT escal. 0.721 82% 12% 55.2 Gy/46 fx./23-29 d.
Disadvantage 0.435 53% 18% not applicable
(geographical miss)
IMRT
[therapeutic gain (late-effect-free TCP) is equal TCP – LER;
* calculations are based on theoretical examples only, and should not
be used as a guidelines for routine practice)]
Conclusions
It seems clear that the IMRT is a “happy hour” option for
critical normal tissues, but in the same time it might be
“double-trouble” for the tumour it the treatment is not
accurately planned. Of great significance is the manner in
which the objectives of optimization are specified. Usual-
ly, they are specified only in terms of the desired physical
dose or dose ranges in the target volume and normal tis-
sues. Pure, physical DVH may increase the potential risk
of geographical miss which always results in dramatic de-
crease of tumour control probability. The present paper
demonstrates that to strengthen IMRT optimization it is
imperative that criteria of optimization should be speci-
fied in a clinically relevant manner, and they should inclu-
de dose-volume effects, normalization of iso-effective do-
ses depending on change in the dose per fraction, TCP
and NTCR indices. Finally BNDVHs should be converted
into the RTOC iso-utility curves which can accurately
Fig. 8. RTOC modelling of iso-benefit (utility) curves to optimize treatment technique and dose fractionation. RTOC curves tangent to the iso-benefit
curve gives the highest “k” value for optimal treatment (see Tab. II)
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and objectively indicate optimal IMRT solution. Under
these circumstances, the use of biological indices and
constraints for small volumes of tumour and critical or-
gans seems less important. However, for large volumes of
anatomic structures such as the lung biological optimi-
zation of IMRT planning is of major importance. It seems
that the use of more than one biological penalty factor
(i.e. TD5 for small and medium or large volume) for criti-
cal organ can improve accuracy of the optimization. Fur-
thermore, IMRT combined with altered dose fractiona-
tion (i.e. accelerated hyperfractionation) may effectively
convert the classical problem of a “double-trouble” into
a “double advantage” because not only the relative dose to
the critical organ is reduced, but the dose per fraction is
also reduced, and the dose within the target can be esca-
lated. However, it has to be acknowledged that for the
majority of tumour types and critical organs the proposed
biological indices are still simplistic and poorly documen-
ted and good data are sparse. Thus, there is the urgent ne-
ed to collect clinical data on tumour and normal tissue ra-
diation response in order to improve optimization of
IMRT planning.
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